Previous close | 0.3000 |
Open | 0.3000 |
Bid | 0.0000 |
Ask | 0.5500 |
Strike | 60.00 |
Expiry date | 2024-01-19 |
Day's range | 0.3000 - 0.3000 |
Contract range | N/A |
Volume | |
Open interest | 28 |
Avantor's (AVTR) latest partnership is expected to significantly optimize labs' inventory management and the overall workflow.
Despite Avantor's (AVTR) strength in bioproduction and strength in Applied Technologies and Advanced Materials end markets, it reports an overall soft Q1 performance.
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 3.57% and 0.85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Avantor, Inc. (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors continue to be optimistic about Avantor's (AVTR) strong product portfolio.
Industry panel recognizes Avantor's outstanding accomplishments in chromatography instruments, chemicals, and consumablesSINGAPORE - ACN Newswire - 16 March 2023 - Avantor, a leading global provider of mission-critical products and services to customers in the life sciences, education, government and advanced technologies & applied materials industries, has been accorded the Best Bioprocessing Company for Chromatography at the Asia-Pacific Bioprocessing Excellence Awards 2023 (ABEA). Narayana Ra
Centene's (CNC) fourth-quarter results suffer from elevated medical expenses, partly offset by growing premium and service revenues.
Despite Avantor's (AVTR) robust core organic sales across its segments, it reports an overall soft Q4 performance.
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 6.67% and 0.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Premier, Inc. (PINC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avantor's (AVTR) robust performance across the majority of its segments drives its Q3 sales, despite business challenges.
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 3.03% and 0.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Avantor, Inc. (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Avantor (AVTR) stock based on the movements in the options market lately.
Major U.S. indices nosedived on Sep 14 following the inflation report for the month of August.
Investors need to pay close attention to Avantor (AVTR) stock based on the movements in the options market lately.
Avantor Foundation grants to healthcare charitable organizations - HealthServe and SATA CommHealth - will aid more than 1,000 beneficiariesSINGAPORE - ACN Newswire - 24 August 2022 - Avantor Foundation, Avantor's philanthropic arm, committed financial resources to healthcare charitable organizations, HealthServe and SATA CommHealth, as part of the Foundation's mission to provide healthcare to those in need. The grants will offer much-needed support to communities who would otherwise be unable to
Avantor's (AVTR) robust performance across majority of its segments drives its Q2 sales, despite business challenges.
Shares of chemical reagents producer Avantor (NYSE: AVTR) are slumping today, down by 10.4% as of 2 p.m. ET, after the company posted a bit of a miss in its Q2 earnings report last night. Expected to earn $0.38 per share on sales of $2 billion, Avantor instead reported a profit of $0.37 per share and sales closer to $1.9 billion. The bad news is that the $0.37 per share that Avantor earned in its fiscal second quarter 2022 was only a pro forma number.
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of -2.63% and 3.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AVTR vs. DOCS: Which Stock Is the Better Value Option?
Solid demand for behavioral healthcare services, growth-related efforts in the form of JVs, declining debt burden and sufficient cash-generating abilities continue to benefit Acadia Healthcare (ACHC).
AVTR vs. DOCS: Which Stock Is the Better Value Option?
The Beauty Health Company (SKIN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.